Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals

IgG anti-SARS-CoV-2 Omicron spike glycoprotein antibodies were detected in 100% of health care workers, a real world population attending general practice for vaccination and haemodialysis patients 4 weeks after a third SARS-CoV-2 vaccine dose (Pfizer-BioNtech 162b2).

Against both Delta and Omicron variants, antibody levels were higher in the cohort who had previously received two doses of AstraZeneca ChAdOx1 nCoV-19 vaccine than two doses of Pfizer-BioNtech 162b2.

Prior to this third vaccine dose and 6 months post second vaccine dose, there was evidence of significant waning of antibody reactivity against Delta and Omicron variants of concern, particularly in individuals initially receiving two doses of AstraZeneca ChAdOx1 nCoV-19.

Author list


Sian Faustini

Adrian Shields

Gemma Banham

Nadezhda Wall

Saly Al-Taei

Chloe Tanner

Zahra Ahmed

Elena Efstathiou

Neal Townsend

Margaret Goodall

Tim Plant

Marisol Perez-Toledo

Aleksandra Jasiulewicz

Ruth Price

James McLaughlin

John Farnan

Julie Moore

Louise Robertson

Andrew Nesbit

Grace Curry

Amy Black

Adam Cunningham

Lorraine Harper

Tara Moore

Mark Drayson

Alex Richter †



Novel Coronavirus SARS-CoV-2


Journal of Infection